PIK3CA and lymphoma: Since initiation of this trial, three PIK3CA inhibitors have been approved by the FDA including, copanlisib (for refractory lymphoma); duvelisib (for refractory CLL and follicular B-cell lymphoma); and alpelisib (for refractory breast cancer) (15–17).